ZA972671B - Pharmaceuticals against diseases of the nervous and cariovascular system. - Google Patents
Pharmaceuticals against diseases of the nervous and cariovascular system.Info
- Publication number
- ZA972671B ZA972671B ZA9702671A ZA972671A ZA972671B ZA 972671 B ZA972671 B ZA 972671B ZA 9702671 A ZA9702671 A ZA 9702671A ZA 972671 A ZA972671 A ZA 972671A ZA 972671 B ZA972671 B ZA 972671B
- Authority
- ZA
- South Africa
- Prior art keywords
- cariovascular
- nervous
- nervous system
- against diseases
- damage
- Prior art date
Links
- 201000010099 disease Diseases 0.000 title 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title 1
- 239000003814 drug Substances 0.000 title 1
- 208000032131 Diabetic Neuropathies Diseases 0.000 abstract 2
- 239000003963 antioxidant agent Substances 0.000 abstract 2
- PHIQHXFUZVPYII-ZCFIWIBFSA-N (R)-carnitine Chemical compound C[N+](C)(C)C[C@H](O)CC([O-])=O PHIQHXFUZVPYII-ZCFIWIBFSA-N 0.000 abstract 1
- 206010022562 Intermittent claudication Diseases 0.000 abstract 1
- 208000028389 Nerve injury Diseases 0.000 abstract 1
- 208000027089 Parkinsonian disease Diseases 0.000 abstract 1
- 206010034010 Parkinsonism Diseases 0.000 abstract 1
- 230000005856 abnormality Effects 0.000 abstract 1
- -1 alkanoyl L-carnitines Chemical class 0.000 abstract 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 abstract 1
- 210000000748 cardiovascular system Anatomy 0.000 abstract 1
- 210000003169 central nervous system Anatomy 0.000 abstract 1
- 206010008129 cerebral palsy Diseases 0.000 abstract 1
- 210000000987 immune system Anatomy 0.000 abstract 1
- 208000014674 injury Diseases 0.000 abstract 1
- 208000021156 intermittent vascular claudication Diseases 0.000 abstract 1
- 229930014626 natural product Natural products 0.000 abstract 1
- 230000008764 nerve damage Effects 0.000 abstract 1
- 229910052760 oxygen Inorganic materials 0.000 abstract 1
- 239000001301 oxygen Substances 0.000 abstract 1
- 210000001428 peripheral nervous system Anatomy 0.000 abstract 1
- 230000002265 prevention Effects 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 239000000126 substance Substances 0.000 abstract 1
- 230000001225 therapeutic effect Effects 0.000 abstract 1
- 230000008733 trauma Effects 0.000 abstract 1
- 230000000472 traumatic effect Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/205—Amine addition salts of organic acids; Inner quaternary ammonium salts, e.g. betaine, carnitine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/365—Lactones
- A61K31/375—Ascorbic acid, i.e. vitamin C; Salts thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
- A61K31/07—Retinol compounds, e.g. vitamin A
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
- A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline
- A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
- A61K31/355—Tocopherols, e.g. vitamin E
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/04—Sulfur, selenium or tellurium; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/06—Tripeptides
- A61K38/063—Glutathione
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Inorganic Chemistry (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Cardiology (AREA)
- Dermatology (AREA)
- Heart & Thoracic Surgery (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Anti-Oxidant Or Stabilizer Compositions (AREA)
- Saccharide Compounds (AREA)
- Fats And Perfumes (AREA)
- Medicines Containing Plant Substances (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| IT96RM000199A IT1283967B1 (it) | 1996-03-29 | 1996-03-29 | Uso di l-carnitina o derivati della l-carnitina ed antiossidanti nella prevenzione e trattamento di patologie derivanti da danni ossidativi |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ZA972671B true ZA972671B (en) | 1998-01-14 |
Family
ID=11404043
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ZA9702671A ZA972671B (en) | 1996-03-29 | 1997-03-27 | Pharmaceuticals against diseases of the nervous and cariovascular system. |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US5998474A (it) |
| EP (1) | EP0797993B1 (it) |
| JP (1) | JPH1087483A (it) |
| KR (1) | KR100489371B1 (it) |
| AT (1) | ATE219360T1 (it) |
| CA (1) | CA2200540C (it) |
| DE (1) | DE69713431T2 (it) |
| DK (1) | DK0797993T3 (it) |
| ES (1) | ES2177843T3 (it) |
| IT (1) | IT1283967B1 (it) |
| PT (1) | PT797993E (it) |
| ZA (1) | ZA972671B (it) |
Families Citing this family (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IT1284661B1 (it) * | 1996-06-06 | 1998-05-21 | Sigma Tau Ind Farmaceuti | Uso di alcanoil l-carnitine nel trattamento terapeutico di malattie infiammatorie croniche intestinali. |
| IT1294227B1 (it) * | 1997-08-01 | 1999-03-24 | Sigma Tau Ind Farmaceuti | Composizione farmaceutica contenente l-carnitina o una alcanoil l-carnitina e alcoli alifatici a lunga catena utile per la prevenzione |
| DE19806890A1 (de) * | 1998-02-19 | 1999-08-26 | Beiersdorf Ag | Kosmetische und dermatologische Wirkstoffkombinationen aus mindestens einer Substanz gewählt aus der Gruppe, bestehend aus Carnitin und den Acylcarnitinen, und mindestens einem Antioxidans sowie Zubereitungen mit einem Gehalt an solchen Wirkstoffkombinationen |
| DE19806946A1 (de) * | 1998-02-19 | 1999-09-09 | Beiersdorf Ag | Kosmetische oder dermatologische Wirkstoffkombinationen aus mindestens einer Substanz gewählt aus der Gruppe, bestehend aus Carnitin und den Acylcarnitinen, und mindestens einem Retinoid sowie Zubereitungen mit einem Gehalt an solchen Wirkstoffkombinationen |
| IT1302125B1 (it) * | 1998-08-03 | 2000-07-31 | Sigma Tau Healthscience Spa | Composizione ad attivita' antiossidante ed antiproliferativacomprendente una carnitina ed un carotenoide |
| IT1302307B1 (it) * | 1998-09-01 | 2000-09-05 | Sigma Tau Healthscience Spa | Composizione ad attivita' antiossidante ed atta a migliorarel'utilizzazione metabolica del glucosio, comprendente acetil |
| IT1302365B1 (it) * | 1998-10-09 | 2000-09-05 | Sigma Tau Healthscience Spa | Uso di carnitine e resveratrolo per produrre una composizione per laprevenzione o il trattamento terapeutico di alterazioni cerebrali |
| AU1295700A (en) * | 1998-11-26 | 2000-06-13 | Sigma-Tau Industrie Farmaceutiche Riunite S.P.A. | Use of fumarate salt of l-carnitine or its alkanoyl derivatives in ischaemia |
| IT1306130B1 (it) * | 1999-04-16 | 2001-05-30 | Sigma Tau Healthscience Spa | Composizione comprendente una carnitina e glutatione, atta adaumentare l'assorbimento del glutatione sinergizzandone gli effetti. |
| US6476010B2 (en) * | 2000-03-10 | 2002-11-05 | Hill's Pet Nutrition | Method for increasing intestinal absorption of fat soluble vitamins in post-menopausal women and lower animals |
| AU2002308648A1 (en) * | 2001-05-04 | 2002-11-18 | Theralife, Inc. | Compositions and methods for reducing cytotoxicity and inhibiting angiogenesis |
| US6923960B2 (en) * | 2001-10-03 | 2005-08-02 | Vsl Pharmaceuticals Inc. | Antioxidant combination composition and use thereof |
| ITRM20010695A1 (it) * | 2001-11-26 | 2003-05-26 | Sigma Tau Ind Farmaceuti | Uso della propionil l-carnitina o di un suo sale farmacologicamente accettabile per la preparazione di un medicamento per il trattamento del |
| FR2842422B1 (fr) | 2002-07-16 | 2006-06-30 | Univ Aix Marseille Ii | Compositions destinees au traitement des neuropathies peripheriques, preparation et utilisations |
| US20040132821A1 (en) * | 2002-10-11 | 2004-07-08 | Roberto Crea | Therapeutic combination of carnitine and antioxidant polyphenols |
| JP2005187454A (ja) * | 2003-12-05 | 2005-07-14 | Sankyo Co Ltd | ビタミンｅ含有ｌｄｌ低下剤及び／又は動脈硬化抑制剤組成物 |
| PT1711070E (pt) | 2004-01-28 | 2016-02-15 | Nestec Sa | Composição nutricional para melhorar o estado da pele e prevenir doenças de pele |
| US20050232911A1 (en) * | 2004-04-19 | 2005-10-20 | Schreiber Brian D | Prevention and treatment of metabolic abnormalities associated with excess intramyocellular lipid |
| US20070225355A1 (en) * | 2004-06-29 | 2007-09-27 | Elixirin Corporation | Dietary Compositions for Enhancing Metabolism and Reducing Reactive Oxygen Species |
| US20100022629A1 (en) * | 2006-01-13 | 2010-01-28 | Elixirin | Dietary Methods and Compositions for Enhancing Metabolism and Reducing Reactive Oxygen Species |
| US20080226696A1 (en) * | 2007-03-15 | 2008-09-18 | Ben Treadwell | Methods of improving learning abilities of aged companion animals |
| US20110015154A1 (en) * | 2009-07-20 | 2011-01-20 | Kellermann Gottfried H | Supporting acetylcholine function |
| US20110098265A1 (en) * | 2009-10-28 | 2011-04-28 | Neuroscience, Inc. | Methods for reducing cravings and impulses associated with addictive and compulsive behaviors |
| EP3125941B1 (en) | 2014-04-01 | 2020-12-16 | H&D S.r.l. | Method for determining the oxidizing power of hydroperoxides rooh in a biological sample |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR4465M (it) * | 1965-06-28 | 1966-09-26 | ||
| US5292538A (en) * | 1992-07-22 | 1994-03-08 | Metagenics, Inc. | Improved sustained energy and anabolic composition and method of making |
| US5397786A (en) * | 1993-01-08 | 1995-03-14 | Simone; Charles B. | Rehydration drink |
| DE4335454A1 (de) * | 1993-10-19 | 1995-04-20 | Schleicher Peter | Geriatrikum |
| IT1275434B (it) * | 1995-05-19 | 1997-08-07 | Farmila Farma Milano | Composizioni farmaceutiche e/o dietetiche ad attivita' antiossidante |
-
1996
- 1996-03-29 IT IT96RM000199A patent/IT1283967B1/it active IP Right Grant
-
1997
- 1997-03-06 PT PT97103727T patent/PT797993E/pt unknown
- 1997-03-06 EP EP97103727A patent/EP0797993B1/en not_active Expired - Lifetime
- 1997-03-06 AT AT97103727T patent/ATE219360T1/de active
- 1997-03-06 ES ES97103727T patent/ES2177843T3/es not_active Expired - Lifetime
- 1997-03-06 DE DE69713431T patent/DE69713431T2/de not_active Expired - Lifetime
- 1997-03-06 DK DK97103727T patent/DK0797993T3/da active
- 1997-03-18 US US08/819,262 patent/US5998474A/en not_active Expired - Lifetime
- 1997-03-20 CA CA2200540A patent/CA2200540C/en not_active Expired - Lifetime
- 1997-03-27 ZA ZA9702671A patent/ZA972671B/xx unknown
- 1997-03-28 JP JP9077376A patent/JPH1087483A/ja active Pending
- 1997-03-29 KR KR1019970011380A patent/KR100489371B1/ko not_active Expired - Lifetime
Also Published As
| Publication number | Publication date |
|---|---|
| DE69713431T2 (de) | 2003-02-13 |
| JPH1087483A (ja) | 1998-04-07 |
| DE69713431D1 (de) | 2002-07-25 |
| US5998474A (en) | 1999-12-07 |
| MX9702280A (es) | 1997-09-30 |
| EP0797993A1 (en) | 1997-10-01 |
| ITRM960199A1 (it) | 1997-09-29 |
| KR100489371B1 (ko) | 2005-08-23 |
| KR970064603A (ko) | 1997-10-13 |
| CA2200540A1 (en) | 1997-09-29 |
| CA2200540C (en) | 2011-06-14 |
| ES2177843T3 (es) | 2002-12-16 |
| DK0797993T3 (da) | 2002-10-07 |
| ITRM960199A0 (it) | 1996-03-29 |
| EP0797993B1 (en) | 2002-06-19 |
| PT797993E (pt) | 2002-11-29 |
| IT1283967B1 (it) | 1998-05-07 |
| ATE219360T1 (de) | 2002-07-15 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ZA972671B (en) | Pharmaceuticals against diseases of the nervous and cariovascular system. | |
| ZA9610769B (en) | Pharmaceutical composition comprising l-carnitine or an alkanoyl l-carnitine in combination with a polyunsaturated fatty acid | |
| CA2192899A1 (en) | Composition containing l-carnitine and hydroxycitric acid | |
| CA2314326A1 (en) | Transdermal therapeutic device and method with capsaicin and capsaicin analogs | |
| MY136927A (en) | Highly purified ethyl epa and other epa derivatives for neurological disorders | |
| EP0196769A3 (en) | A novel transdermal pharmaceutical absorption dosage unit | |
| IL104006A (en) | Azaheterocyclylmethyl-chromans their preparation and pharmaceutical compositions containing them | |
| IL82823A (en) | Controlled release oral dosage formulation of a combination of carbidopa and levodopa in the treatment of parkinsonism | |
| AU7185294A (en) | Effervescent system with an alkali- and/or metal-sensitive pharmaceutical active substance and process for producing the same | |
| SG50339A1 (en) | Fatty acid derivatives | |
| CA2109098A1 (en) | Activity-dependent neurotrophic factor | |
| CA2295746A1 (en) | Composition comprising l-carnitine or an alkanoyl l-carnitine and long-chain alkanols | |
| AU1376497A (en) | Medicament intended to the treatment of obsessive compulsive troubles, sleep apnoea, sexual dysfunctions, emesa and transport sickness | |
| CA2108330A1 (en) | Enhancer for the Antianemia Effect of Erythropoietin and Method of Augmenting the Antianemia Effect of Erythropoietin | |
| CA2297153A1 (en) | Use of alkanoyl carnitine derivatives for the treatment of attention-deficit/hyperactive disorders | |
| TW282468B (it) | ||
| Webster et al. | Circulating prostacyclin concentrations may be increased by bendrofluazide in patients with essential hypertension | |
| DE3476736D1 (en) | Use of an antihypoxidoticum with cerebral and peripheral effect | |
| CA2147594A1 (en) | Procedure for the Obtainment of 1-(5-Bromofur-2-IL)-2-Bromo-2-Nitroethene and Its Microcide Action | |
| HK1013962A (en) | Pharmaceutical composition containing gamma-hydroxybutyric acid or its lactone in the treatment of drug dependence and nutritional disorders | |
| 朱亚玲 et al. | EFFECTS OF CALCIUM AND CALMODULIN INHIBITORS ON THE ABNORMAL PROLIFERATION OF LUNG FIBROBLAST | |
| WO2001034178A3 (en) | Methods and compositions for treatment of traumatic brain injury | |
| IT1260150B (it) | Processo per la purificazione di forme mutate monomeriche del fattore neuronotrofico ciliare umano | |
| MX9603241A (es) | Productos farmaceuticos para curar enfermedades tumorales y procedimiento para su preparacion. | |
| TH54050A (th) | เอทิลอีพีเอ ที่ทำให้บริสุทธิ์อย่างมากและอนุพันธ์อีพีเออื่นๆ ที่ใช้รักษาโรคทางจิตเวชและโรคทางประสาท |